Influenza surveillance mechanisms in Mexico were adequate during the fast-spreading H1N1 outbreak in 2009, yet Mexico did not have the infrastructure to quickly identify the emergence of this novel strain, according to an Arizona State University (ASU) epidemiologist. Продолжить чтение

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (ЧМП) of the European Medicines Agency has adopted a negative opinion on its Marketing Authorisation Application (СТРАНА) for the antibiotic ZEFTERA(TM) (ceftobiprole medocaril), for the treatment of complicated skin and soft tissue infections. Продолжить чтение

Сегодня, Polyphor Ltd published the discovery of a new class of antibiotics with a novel mode of action (Наука, Том 327, проблема 5968). This proprietary new class of antibiotics is effective against multi-drug resistant Gram-negative bacteria, opening up new treatment options for serious and often life-threatening infections. The most advanced drug candidate in this new class, POL7080, selectively kills the dangerous bacteria Pseudomonas aeruginosa. Продолжить чтение

GeoVax Labs, Inc., Атлант, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Вирус иммунодефицита человека), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) в Сан-Франциско. Продолжить чтение

Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. Фазы 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels. Продолжить чтение

Otonomy, Inc. сегодня объявила о том, что США. Продукты питания и лекарственных препаратов (УЛХ) has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of OTO-104 in patients with Meniere’s disease, a debilitating disorder of the inner ear affecting balance and hearing. Продолжить чтение

Researchers investigating UK samples have found no association between the controversial xenotropic murine leukaemia virus-related virus (XMRV) and chronic fatigue syndrome (CFS). Продолжить чтение

MAP Pharmaceuticals, Inc. today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine. Продолжить чтение

Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Лекарства и Медицинские препараты Агентство по регулированию (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Продукты питания и лекарственных препаратов (УЛХ) under the Special Protocol Assessment (SPA) Процесс. Продолжить чтение

Helix BioPharma Corp. today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings. Продолжить чтение